What is claimed is:

1. A process for preparing a pharmacologically active compound, which comprises:
   (a) preparing a pharmacologically active compound comprising an Fc domain;
   (b) treating the pharmacologically active compound with a copper (II) halide; and
   (c) isolating the treated fusion molecule.
2. The process of Claim 1, wherein the pharmacologically active compound is a fusion molecule comprising a pharmacologically active domain and an Fc domain.
3. The process of Claim 1, wherein the pharmacologically active compound comprises an antibody.
4. The process of Claim 1, wherein the copper (II) halide is $CuCl_2$.
5. The process of Claim 1, wherein the pharmacologically active compound is prepared in E coli.
6. The process of Claim 4, wherein the copper (II) halide is $CuCl_2$.
7. The process of Claim 6, wherein the $CuCl_2$ is used in a concentration of at least about 10 mM.
8. The process of Claim 1, wherein the pharmacologically active compound is prepared in CHO cells.
9. The process of Claim 8, wherein the copper (II) halide is $CuCl_2$.
10. The process of Claim 9, wherein the $CuCl_2$ is used in a concentration of at least about 30 mM.
11. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of an OPG protein.
12. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of a leptin protein.

13. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of a TNF-α inhibitor.

14. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of an IL-1 inhibitor.

15. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of an IL-1ra protein.

16. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of a TPO-mimetic peptide.

17. A process for preparing a pharmacologically active compound, which comprises:

(a) preparing a pharmacologically active compound comprising an Fc domain;

(b) treating the fusion molecule with guanidine HCl at a concentration of at least about 4 M;

(c) increasing the pH to about 8.5; and

(d) isolating the treated fusion molecule.

18. The process of Claim 17, wherein the pharmacologically active compound is a fusion molecule comprising a pharmacologically active domain and an Fc domain.

19. The process of Claim 17, wherein the pharmacologically active compound comprises an antibody.

20. The process of Claim 17, wherein the pharmacologically active compound is prepared in E coli.

21. The process of Claim 18, wherein the pharmacologically active compound is prepared in CHO cells.

22. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of an OPG protein.

23. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of a leptin protein.

24. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of a TNF-α inhibitor.

25. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of an IL-1 inhibitor.

26. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of an IL-1ra protein.

27. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of a TPO-mimetic peptide.

28. The process of Claim 1, wherein the Fc domain is an IgG1 Fc domain.

29. The process of Claim 17, wherein the Fc domain is an IgG1 Fc domain.

30. The process of Claim 1, wherein the Fc domain comprises the sequence of SEQ ID NO: 2.

31. The process of Claim 17, wherein the Fc domain comprises the sequence of SEQ ID NO: 2.